<VariationArchive VariationID="2426757" VariationName="NC_000005.9:g.(?_176720813)_(176722460_?)del" VariationType="Deletion" Accession="VCV002426757" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-29" DateCreated="2023-02-13" MostRecentSubmission="2023-06-10">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1950949" VariationID="2426757">
      <GeneList>
        <Gene Symbol="NSD1" FullName="nuclear receptor binding SET domain protein 1" GeneID="64324" HGNC_ID="HGNC:14234" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>5q35.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="177131798" stop="177300213" display_start="177131798" display_stop="177300213" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="176560079" stop="176727213" display_start="176560079" display_stop="176727213" Strand="+" />
          </Location>
          <OMIM>606681</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NSD1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NSD1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000005.9:g.(?_176720813)_(176722460_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>5q35.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" innerStart="176720813" innerStop="176722460" display_start="176720813" display_stop="176722460" variantLength="1648" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.9" sequenceAccession="NC_000005" sequenceVersion="9" change="g.(?_176720813)_(176722460_?)del" Assembly="GRCh37">
            <Expression>NC_000005.9:g.(?_176720813)_(176722460_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000005.9:g.(?_176720813)_(176722460_?)del AND Sotos syndrome" Accession="RCV003232858" Version="8">
        <ClassifiedConditionList TraitSetID="32529">
          <ClassifiedCondition DB="MedGen" ID="C0175695">Sotos syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-12-13" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2023-06-10">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="32529" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="36672" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cerebral gigantism</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Sotos syndrome</ElementValue>
                <XRef ID="MONDO:0019349" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS117550" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Distinctive facial appearance, overgrowth in childhood, and learning disabilities or delayed development</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sotos' syndrome</ElementValue>
                <XRef ID="Sotos+syndrome/6665" DB="Genetic Alliance" />
                <XRef ID="75968004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CHROMOSOME 5q35 DELETION SYNDROME</ElementValue>
                <XRef Type="MIM" ID="117550" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SOTOS SYNDROME 1</ElementValue>
                <XRef Type="MIM" ID="117550" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">SOTOS</ElementValue>
                <XRef Type="MIM" ID="117550" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10091" />
                <XRef ID="10091" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Sotos syndrome is characterized by a distinctive facial appearance (broad and prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, long chin); learning disability (early developmental delay, mild-to-severe intellectual impairment); and overgrowth (height and/or head circumference â‰¥2 SD above the mean). These three clinical features are considered the cardinal features of Sotos syndrome. Major features of Sotos syndrome include behavioral problems (most notably autistic spectrum disorder), advanced bone age, cardiac anomalies, cranial MRI/CT abnormalities, joint hyperlaxity with or without pes planus, maternal preeclampsia, neonatal complications, renal anomalies, scoliosis, and seizures.</Attribute>
                <XRef ID="NBK1479" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301652</ID>
                <ID Source="BookShelf">NBK1479</ID>
              </Citation>
              <XRef ID="821" DB="Orphanet" />
              <XRef ID="C0175695" DB="MedGen" />
              <XRef ID="MONDO:0019349" DB="MONDO" />
              <XRef Type="MIM" ID="117550" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7075720" SubmissionDate="2023-02-03" DateLastUpdated="2023-06-10" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_022455.4_5_Deletion (exon 23)|MedGen:C4551477" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003791913" DateUpdated="2023-06-10" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 23 of the NSD1 gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. This variant has not been reported in the literature in individuals affected with NSD1-related conditions. This variant disrupts a region of the NSD1 protein in which other variant(s) (p.Cys2159Ser) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NSD1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000005.9:g.(?_176720813)_(176722460_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C4551477" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
  </ClassifiedRecord>
</VariationArchive>

